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Effect of rosiglitazone on the risk of myocardial infarction and death
from cardiovascular causes
Nissen SE, Wolski K. N Engl J Med 2007;356:2457-71.
Conclusion: Rosiglitazone is associated with an increase in myocardial
infarction and risk of death from cardiovascular causes.
Summary: Rosiglitazone was introduced in 1999 as oral treatment for
type 2 diabetes. It is widely used as monotherapy or in fixed-dose combina-
tions with either metformin or glimepirid. Rosiglitazone acts to lower blood
sugar by increasing insulin sensitivity of peripheral tissues. Individual studies
of rosiglitazone have confirmed its effect on reduction of blood sugar and
improvement in glycosylated hemoglobin levels. Studies, however, were not
powered to assess cardiovascular morbidity and mortality. In this article the
authors reported results of a meta-analysis that included published literature,
the Food and Drug Administration Web site, and a clinical trials registry
maintained by GalxoSmithKline, the manufacturer of rosiglitazone. The
analysis included studies that had a duration of 24 weeks, used a random-
ized control group, and provided outcome data for myocardial infarction
and death from cardiovascular causes. Of 116 potentially relevant studies,
only 42 met the inclusion criteria for the analysis. Focus was on tabulation of
all occurrences of myocardial infarction and death from cardiovascular causes.
A fixed-effect model was used to combine the data. In the 42 trials, the
mean age of subjects was 56 years and the mean glycosylated hemoglobin level
was 8.2%. The odds ratio for myocardial infarction in the rosiglitazone group
comparedwith the control groupswas 1.43 (95% confidence interval [CI], 1.03
to 1.98; P  .03). The odds ratio for death from cardiovascular causes in
patients taking rosiglitazone versus controls was 1.64 (95% CI, 0.98 to 2.74; P
 .06).
Comment: The authors acknowledge in the discussion of the article
that a few events either way may have influenced the results of this analysis.
Nevertheless, there seems to be no particular benefit for rosiglitazone other
than reducing laboratory measures of glycemic control. Rosiglitazone has no
known favorable effect on microvascular disease or other complications of
diabetes. Given the results of this study, there seems little rationale for
continued use of rosiglitazone for treatment of type 2 diabetes.
Elastin stabilization for treatment of abdominal aortic aneurysms
Isenburg JC, Simionescu DT, Starcher BC, et al. Circulation 2007;115:
1729-37.
Conclusion: Administration of pentagalloyl glucose (PGG) in the
periadventitial area of the aorta slows development of abdominal aortic
aneurysm (AAA) in an animal model.
Summary: Among other things, AAA is characterized by disruption or
fragmentation of elastin and decreasedmedial elastin content. Treatment for
AAA is surgical, and no pharmacologic therapy currently exists. In this
article, the authors sought to explore the role of PGG, a potential elastin-
stabilizing agent, for treatment of AAA.
PGG is a polyphenolic tannin. Tannins bind to elastin and make them
resistant to enzymatic degradation. The authors tested the ability of PGG to
enhance elastin stability and interfere with AAA development in a well-
established AAA model in rats that uses calcium chloride to mediate aortic
injury and induce an AAA. In calcium chloride-induced aneurysms, the
authors delivered PPG periadventitially at two separate time points during
AAA development. They then measured aortic diameter, elastin integrity,
and other pathologic markers in PGG-treated aortas compared with saline-
treated control aortas.
The periadventitial delivery of noncytotoxic levels of PGG inhibited elastin
degeneration and attenuatedAAAexpansion. PPGhinderedAAAdevelopment
in themodel without apparent effects on inflammation, calcification, andMMP
activity. Despite high levels of proteinases from inflammatory cells in the wall of
the aorta, PGG appeared to preserve the integrity of elastic lamina.
Comment: Growth of AAAs appears to be associated with elastin
degeneration secondary to proteinases derived from inflammatory cells
infiltrating the aortic wall. By directly targeting what appears to be one of the
primary biochemical mechanisms of AAA development, this article suggests
a pharmacologic therapy for AAA. Refining delivery mechanisms and dosage
intervals are obviously future areas of research in this field.
Impact of obesity in arteriovenous fistula outcomes in dialysis patients
Kats N, Hawxby AM, Barker J, et al. Kidney Int 2007;71:39-43.
Conclusion: Obese patients have worse fistula survival than nonobese
patients because of a high secondary failure rate of the fistula.
Summary: There appears to be a less frequent use of fistulas vs grafts in
obese vs nonobese patients requiring hemodialysis. The reasons for this
discrepancy are unclear and may be because in obese patients there is a lower
rate of fistula placement, a higher primary failure rate (a fistula that was never
usable for dialysis) of fistulas, or higher secondary failure rates (a fistula that
failed after being used successfully for dialysis).
In this study, the authors used an institutional prospective computer-
ized vascular access database to identify patients receiving a first fistula or
graft during a 2-year period. Access outcomes were compared between
obese and nonobese patients. Obese patients were defined as those having a
body mass index (BMI) 30 kg/m2.
During the study period, a first fistula was placed in 183 patients and a
first graft in 205. Fifty-four of the fistula patients were obese, and 129 were
not obese. Patient age, frequency of diabetes, coronary artery disease,
peripheral vascular disease, and obesity were not different between patients
receiving a fistula and those receiving a graft. Obese and nonobese patients
were equally likely to receive a fistula (47.4% vs 47.1%). Primary failure rate
of fistulas was similar in both obese and nonobese patients (46% vs 41%, P
.45). If a fistula was useful for dialysis, secondary survival was worse in obese
patients (hazard ratio, 2.74; 95% conference interval [CI], 1.48 to 7.90; P
.004). Secondary fistula survival in obese vs nonobese patients was 68% vs
92% at 1 year, 59% vs 78% at 2 years, and 47% vs 70% at 3 years. A multiple
variable survival analysis model that included age, sex, race, diabetes, coro-
nary artery disease, peripheral vascular disease, fistula location, surgeon and
obesity, found that obesity was the only factor predicting secondary fistula
failure (hazard ratio, 2.93; 95% CI, 1.44 to 5.93; P  .004).
Comment: The authors found that many of the potential explanations
for fistula failure in the obese patient vs the nonobese patient did not hold up
to statistical analysis. Specifically, there was no difference in venous diame-
ters, prevalence of transposed vein fistulas, or the prevalence of needle
infiltration in the obese vs nonobese patient. A previous study (Am J Kidney
Diseases 2002; 39: 92-101) found no association between BMI and risk of
primary fistula failure. In that study, 90% of the patients were white,
whereas in the current study, the primary population was black. It may be
that unknown confounding variables other than obesity are contributing to
the higher secondary fistula failure rate in the obese patient.
Mutations in FOXC2 are strongly associated with primary valve failure
in veins of the lower limb
Mellor RH, Brice G, Stanton A.WB, et al. Circulation 2007;115:1912-20.
Conclusion: Mutations in the FOXC2 gene are strongly associated
with primary venous valve failure in both deep and superficial veins of the
lower extremity.
Summary: FOXC2 is situated on chromosome 16Q24.3 and encodes a
regulatory transcription factor that is implicated in vascular and lymphatic
development. It is expressed on both endothelial and smooth muscle cells of
developing blood vessels and is also expressed on venous and lymphatic valve
leaflets. Homozygous male mice for FOXC2 die during development with
nonfunctioning blood vessels. A heterozygous mutation of FOXC2 in humans
results in lymphedema distichiasis, an inherited form of lymphedema. Patients
with lymphedema distichiasis often have varicose veins. This form of lymphed-
ema is thought to be caused by lymphatic valve reflux, and because FOXC2 is
highly expressed on mouse embryo venous valves, the authors postulated
FOXC2mutations may be linked to venous valve failure and venous reflux.
The authors identified 18 subjects with a FOXC2 mutation, three of
whom did not have lymphedema. All 18 subjects were studied with duplex
ultrasound imaging of the lower extremities for evidence of venous reflux.
Criteria for venous reflux included peak reflux velocity of 10 cm/s and
duration of reflux 0.5 seconds after release of distal compression. In this
study, pathologic reflux was only diagnosed if both of these criteria were
present. The subjects with FOXC2 mutations were compared with a refer-
ence group of 12 subjects with no FOXC2mutation. Ten of these reference
subjects were family members of participants in the FOXC2 group. Every
individual with the FOXC2 mutation showed reflux in the great saphenous
vein, but only one of 12 of the reference subjects showed reflux in the great
saphenous vein (P  .0001). Deep venous reflux was also recorded in 14 of
the 18 subjects with the FOXC2 mutation.
Comment: This is the first paper to identify a link between a specific
genetic mutation and primary venous valve failure in superficial and deep
veins. It appears that FOXC2 expression is required for valve development
and maintenance of valvular integrity in the venous system of the lower
extremities in humans. The role of FOXC2 mutations in determining
primary venous valve failure in the population in general certainly seems
worth investigating.
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